LinkedInFacebookTwitterRssEmail
(832) 968-8698|sales@avancebio.com

News & Events

17 10, 2025

Technote: Successful Development of Cell-based Potency Assays

2025-10-17T21:02:01+00:00

Download our technote, Successful Development of Cell-based Potency Assays, to explore the essential role of potency assays in evaluating the biological activity of complex therapeutics, including cell and gene therapy products. This comprehensive guide draws on our extensive experience designing and validating custom potency assays, offering practical insights into assay formats, MOA selection, and relative potency determination...

Technote: Successful Development of Cell-based Potency Assays2025-10-17T21:02:01+00:00
17 10, 2025

Poster Presentation: Digitally Secure Sequencing – Implementing Part 11 Ready NGS Data Security in a CRO Environment

2025-10-17T20:07:36+00:00

Next- and third-generation sequencing are vital for GMP, GLP, and clinical applications, but data integrity challenges and 21 CFR Part 11 compliance require secure instruments, validated workflows, and robust audit trails...

Poster Presentation: Digitally Secure Sequencing – Implementing Part 11 Ready NGS Data Security in a CRO Environment2025-10-17T20:07:36+00:00
17 10, 2025

Poster Presentation: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq

2025-10-17T20:41:07+00:00

Genome editing offers unprecedented precision, but off-target effects remain a key safety concern. GUIDE-Seq provides a high-throughput, genome-wide method to map CRISPR-Cas activity in living cells, enabling researchers to assess specificity and ensure safer gene-editing therapies...

Poster Presentation: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq2025-10-17T20:41:07+00:00
7 10, 2025

World ADC Conference – 2025

2025-10-09T20:15:09+00:00

Avance Biosciences is proud to participate in the 2025 World ADC Conference, highlighting our CGMP- and GLP-compliant analytical expertise supporting the development of antibody-drug conjugates. From assay development and validation to comprehensive bioanalytical testing, our services empower biopharmaceutical innovators to advance safer, more effective targeted therapies.[...]

World ADC Conference – 20252025-10-09T20:15:09+00:00
1 10, 2025

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Abeta40 in patients with mild cognitive impairment or very mild Alzheimer’s disease: A randomized, double-blind, placebo-controlled phase 2 study

2025-10-01T00:00:00+00:00

INTRODUCTION: ABvac40 is an investigational active immunotherapy (vaccine) targeting Abeta40. This study assessed the safety and immunogenicity of ABvac40 in patients with amnestic mild cognitive impairment or very mild Alzheimer's disease. METHODS: AB1601 was a multicenter, randomized, double-blind, placebo-controlled phase 2 study. Patients (n = 124) received five monthly injections plus a 10-month booster of [...]

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Abeta40 in patients with mild cognitive impairment or very mild Alzheimer’s disease: A randomized, double-blind, placebo-controlled phase 2 study2025-10-01T00:00:00+00:00
1 10, 2025

A Fit-for-purpose Strategy for Clinical Immunogenicity Assessment of Multivalent Bispecific Antibodies

2025-10-01T00:00:00+00:00

Bispecific antibodies (BsAbs) have emerged as a promising class of therapeutics to treat complex diseases, offering advantages in dual targeting simultaneously compared to monospecific antibodies. However, BsAbs often require advanced engineering, and the novel formats present challenges for the development of clinical anti-drug antibody (ADA) assays. Immunogenicity evaluation is a required study endpoint during the [...]

A Fit-for-purpose Strategy for Clinical Immunogenicity Assessment of Multivalent Bispecific Antibodies2025-10-01T00:00:00+00:00
15 09, 2025

Sept 15-18 – BioProcess International – 2025

2025-09-24T19:44:41+00:00

Avance Biosciences™ will exhibit at BPI International 2025 in Boston, showcasing our end-to-end analytical and testing services for biologics, cell, and gene therapies. Visit booth 1508 to learn about our NGS Center of Excellence, offering advanced sequencing, on/off-target detection, and gene editing safety assessments...

Sept 15-18 – BioProcess International – 20252025-09-24T19:44:41+00:00
12 09, 2025

Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy

2025-09-12T00:00:00+00:00

PTDSS1 (phosphatidylserine synthase 1) encodes an enzyme that facilitates production of phosphatidylserine (PS), which mediates a global immunosuppressive signal. Here, based on in vivo CRISPR screen, we identified PTDSS1 as a target to improve anti-PD-1 therapy. Depletion of Ptdss1 in tumor cells increased expression of interferon-gamma (IFN-gamma)-regulated genes, including B2m, Cxcl9, Cxcl10, and Stat1, even [...]

Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy2025-09-12T00:00:00+00:00
Go to Top